David J. Taber

David J. Taber

Auto-generated profile, based on publicly available information

David J. Taber

Department of Surgery, Medical University of South Carolina, Charleston, South Carolina

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2020 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
NPNicole A. Pilch
Nicole A. Pilch
LBLyndsey J. Bowman
Lyndsey J. Bowman
DTDavid J. Taber
David J. Taber

14 May 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
HGHaley M. Gonzales
Haley M. Gonzales
JMJohn W. McGillicuddy
John W. McGillicuddy
VRVinayak Rohan
Vinayak Rohan
JCJessica Chandler
Jessica Chandler
SNSatish N. Nadig
Satish N. Nadig
DTDavid J. Taber
David J. Taber
Tacrolimus (Tac) is widely used to prevent rejection and graft loss in solid‐organ transplantation. A limiting characteristic of Tac is the high intra and interpatient variability associated with its use. Routine therapeutic drug monitoring (TDM) is necessary to facilitate Tac management and avoid undesirable clinical outcomes. However, whole blood trough concentrations commonly utilized in TDM are not strong predictors of the detrimental clinical outcomes of interest. Recently, researchers have focused on Tac intra‐patient variability (Tac IPV) as a novel marker to better assess patient risk. Higher Tac IPV has been associated with a number of mechanisms leading to shortened graft survival. Medication nonadherence (MNA) is considered to be the primary determinant of high Tac IPV and perhaps the most modifiable risk factor. An understanding of methodology behind Tac IPV is imperative to its recognition as an important prognostic measure and integration into clinical practice. Therapeutic interventions targeting MNA and reducing Tac IPV are crucial to improving long‐term graft survival.

2 December 2016 in American Journal of Nephrology
Verified
Journal Article
Open access
PDF file
DTDavid J. Taber
David J. Taber
JFJames N. Fleming
James N. Fleming
CFCory E. Fominaya
Cory E. Fominaya
Mulugeta GebregziabherMulugeta Gebregziabher
Mulugeta Gebregziabher
KHKelly J. Hunt
Kelly J. Hunt
LELeonard E. Egede
Leonard E. Egede
Background: Non-adherence to medication is a well-studied and known cause of late allograft loss, but it is difficult to measure and prospectively monitor. The aim of this study was to assess if appointment non-adherence was correlated with medication non-adherence and a predictor of graft outcomes. Methods: This was a longitudinal cohort study that used the National United States Renal Data System and veterans affairs health records data with time-to-event analyses conducted to assess the impact on graft and patient survival. Results: The number of transplants that were included in the analysis was 4,646 (3,656 with complete records); 14.6% of patients had an appointment no show rate of ≥12% (non-adherence). Appointment and medication non-adherence were highly correlated and both were significant independent predictors of outcomes. Those with appointment non-adherence had 1.5 times the risk of acute rejection (22.0 vs. 14.7%, p < 0.0001) and a 65% higher risk of graft loss (adjusted hazards ratio (aHR) 1.65, 95% CI 1.38-1.97, p < 0.0001). There was a significant interaction between appointment and medication non-adherence; those with appointment and medication non-adherence were at very high risk of graft loss (aHR 4.18, 95% CI 3.39-5.15, p < 0.0001), compared to those with only appointment non-adherence (aHR 1.39, 95% CI 0.97-2.01, p = 0.0766) or only medication non-adherence (aHR 2.44, 95% CI 2.11-2.81, p < 0.0001). Conclusion: These results demonstrate that non-adherence to health care appointments is a significant and independent risk factor for graft loss.

1 December 2017 in Transplantation
Verified
Journal Article
Closed access
DTDavid J. Taber
David J. Taber
ZSZemin Su
Zemin Su
JFJames N. Fleming
James N. Fleming
JMJohn W. McGillicuddy
John W. McGillicuddy
MPMaria A. Posadas-Salas
Maria A. Posadas-Salas
PBPrabhakar K. Baliga
Prabhakar K. Baliga
Background Low tacrolimus concentrations have been associated with higher risk of acute rejection, particularly within African American (AA) kidney transplant recipients; little is known about intrapatient tacrolimus variabilities impact on racial disparities. Methods Ten year, single-center, longitudinal cohort study of kidney recipients. Intrapatient tacrolimus variability was assessed using the coefficient of variation (CV) measured between 1 month posttransplant and the clinical event, with a comparable period assessed in those without events. Pediatrics, nontacrolimus/mycophenolate regimens, and nonrenal transplants were excluded. Multivariable Cox regression models were used to analyze data. Results One thousand four hundred eleven recipients were included (54.4% AA) with 39 521 concentrations used to assess intrapatient tacrolimus CV. Overall, intrapatient tacrolimus CV was higher in AAs versus non-AAs (39.9 ± 19.8 % vs 34.8 ± 15.8% P < 0.001). Tacrolimus variability was a significant risk factor for deleterious clinical outcomes. A 10% increase in tacrolimus CV augmented the risk of acute rejection by 20% (adjusted hazard ratio, 1.20, 1.13-1.28; P < 0.001) and the risk of graft loss by 30% (adjusted hazard ratio, 1.30, 1.23-1.37; P < 0.001), with significant effect modification by race for acute rejection, but not graft loss. High tacrolimus variability (CV >40%) was a significant explanatory variable for disparities in AAs; the crude relative risk of acute rejection in AAs was reduced by 46% when including tacrolimus variability in modeling and reduced by 40% for graft loss. Conclusions These data demonstrate that intrapatient tacrolimus variability is strongly associated with acute rejection in AAs and graft loss in all patients. Tacrolimus variability is a significant explanatory variable for disparities in AA recipients.

6 February 2013 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
DTDavid J. Taber
David J. Taber
HMHolly B. Meadows
Holly B. Meadows
NPNicole A. Pilch
Nicole A. Pilch
KCKenneth D. Chavin
Kenneth D. Chavin
PBPrabhakar K. Baliga
Prabhakar K. Baliga
LELeonard E. Egede
Leonard E. Egede

23 May 2015 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
DTDavid J. Taber
David J. Taber
Mulugeta GebregziabherMulugeta Gebregziabher
Mulugeta Gebregziabher
TSTitte R. Srinivas
Titte R. Srinivas
KCKenneth D. Chavin
Kenneth D. Chavin
PBPrabhakar K. Baliga
Prabhakar K. Baliga
LELeonard E. Egede
Leonard E. Egede